10-Q: Caribou Biosciences Reports Mixed Q3 2024 Results Amidst Clinical Trial Progress and Restructuring

Caribou Biosciences' third-quarter report reveals a complex picture of financial challenges and clinical advancements in its CRISPR-based cell therapy programs.

Summary

• Caribou Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $34.7 million for Q3 2024, compared to a $10.0 million loss in Q3 2023.
• Revenue for Q3 2024 was $2.0 million, down from $23.7 million in Q3 2023, primarily due to the termination of the AbbVie Agreement.
• Research and development expenses increased slightly to $30.4 million in Q3 2024, up from $28.6 million in Q3 2023.
• General and administrative expenses remained relatively flat at $9.8 million in Q3 2024.
• The company announced a 12% workforce reduction in July 2024 to extend its cash runway into the second half of 2026.
• Caribou is advancing its allogeneic CAR-T cell therapy pipeline, with clinical trials underway for CB-010, CB-011, and CB-012.
• The company presented updated data from the ANTLER phase 1 trial for CB-010 in r/r B-NHL at the ASCO Annual Meeting in June 2024.
• A retrospective analysis of ANTLER data suggested that partial HLA matching may improve patient outcomes, leading to a new cohort in the trial.
• Caribou plans to initiate a pivotal phase 3 trial for CB-010 in 2L LBCL in the second half of 2025, pending FDA agreement.
• The company is also expanding CB-010 development into autoimmune diseases, with the GALLOP phase 1 trial in LN and ERL expected to start by year-end 2024.
• Initial data from the CaMMouflage phase 1 trial for CB-011 in r/r MM is expected in the first half of 2025.
• Updates on dose escalation for the AMpLify phase 1 trial for CB-012 in r/r AML will be provided as the trial progresses.
• As of September 30, 2024, Caribou had $281.0 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline and a strong cash position, the financial results are worse than expected, with declining revenue and increasing losses. The workforce reduction and settlement of the Bergman Case also contribute to a somewhat negative sentiment.

Positives

• Presented positive clinical data for CB-010 at the ASCO Annual Meeting, demonstrating potential for improved efficacy with partial HLA matching.
• Advancing CB-010 towards a pivotal phase 3 trial in 2L LBCL, planned for the second half of 2025.
• Expanding clinical development of CB-010 into autoimmune diseases, with the GALLOP trial expected to initiate by year-end 2024.
• Progressing CB-011 and CB-012 in phase 1 clinical trials for r/r MM and r/r AML, respectively.
• Received multiple FDA designations for CB-010, CB-011, and CB-012, including RMAT, fast track, and orphan drug designations.
• Maintains a strong cash position of $281.0 million, sufficient to fund operations for at least the next 12 months.
• Successfully negotiated a settlement in the Bergman Case, resolving potential litigation risk.

Negatives

• Reported a significant decrease in revenue for Q3 2024 compared to Q3 2023, primarily due to the termination of the AbbVie Agreement.
• Incurred a larger net loss of $34.7 million in Q3 2024 compared to $10.0 million in Q3 2023.
• Experienced an increase in research and development expenses in Q3 2024 compared to the same period last year.
• Announced a workforce reduction of approximately 12% in July 2024, resulting in $0.6 million in non-recurring restructuring charges.
• The company has a history of operating losses and expects to continue incurring substantial losses in the future.

Risks

• The company has a limited operating history and a history of net operating losses, raising concerns about its ability to achieve profitability.
• The development of cell therapy products is inherently risky, with no guarantee of success in clinical trials or regulatory approval.
• Initial clinical trial data may not be predictive of future results, and outcomes may differ as more data becomes available.
• The company may face challenges in obtaining and maintaining regulatory approval for its product candidates.
• Even if approved, the company's products may not gain market acceptance due to negative public opinion or increased regulatory scrutiny.
• The company may face difficulties in establishing and maintaining intellectual property rights covering its product candidates and technology.
• Competitors may develop more effective or commercially successful therapies, impacting the company's market position.
• The company relies on third parties to conduct clinical trials and manufacture its product candidates, which could lead to delays or quality issues.
• Public health crises or geopolitical events could disrupt the company's business and operations.
• The company may need to raise additional capital to fund its operations, which may not be available on favorable terms or at all.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund its current operating plan for at least the next 12 months. They plan to initiate a pivotal phase 3 trial for CB-010 in 2L LBCL in the second half of 2025 and start the GALLOP trial for CB-010 in LN and ERL by year-end 2024. Initial data from the CaMMouflage trial for CB-011 is expected in the first half of 2025.

Management Comments

• The offer letter to Tina Albertson states 'On behalf of Caribou Biosciences, Inc. (the Company or Caribou), I am pleased to invite you to join the Company as a Chief Medical Officer, reporting to Rachel Haurwitz, PhD.'

Industry Context

Caribou Biosciences operates in the highly competitive and rapidly evolving field of gene editing and cell therapy. The company's focus on allogeneic CAR-T cell therapies addresses the growing demand for off-the-shelf cancer treatments. The development of CRISPR-based therapies is a major trend in the biopharmaceutical industry, with many companies pursuing similar approaches.

Comparison to Industry Standards

• Caribou's allogeneic CAR-T cell therapy approach is similar to that of Allogene Therapeutics, which is developing ALLO-501A, an allogeneic anti-CD19 CAR-T cell therapy, for the treatment of r/r NHL. Allogene reported positive results from its ALPHA2 trial of ALLO-501A in r/r NHL, with a complete response rate of 44% and a median duration of response of 23.1 months.
• Caribou's CB-011, an allogeneic anti-BCMA CAR-T cell therapy, is similar to that of CRISPR Therapeutics and Vertex Pharmaceuticals, which are developing CTX130, an allogeneic anti-CD70 CAR-T cell therapy, for the treatment of r/r MM. CRISPR Therapeutics and Vertex Pharmaceuticals reported positive results from its COBALT-LYM trial of CTX130 in r/r NHL, with a complete response rate of 47% and a median duration of response of 18.4 months.
• Caribou's CB-012, an allogeneic CAR-T cell therapy targeting CLL-1, is similar to that of Fate Therapeutics, which is developing FT536, an allogeneic CAR-NK cell therapy targeting CLL-1, for the treatment of r/r AML. Fate Therapeutics reported positive results from its Phase 1 trial of FT536 in r/r AML, with a complete response rate of 75% and a median duration of response of 8.2 months.
• Compared to these companies, Caribou's clinical programs are at a similar stage of development, with multiple ongoing phase 1 trials. However, Caribou's financial performance, particularly its revenue decline due to the termination of the AbbVie Agreement, lags behind some of its competitors.

Management Changes

Legal Proceedings

• On April 11, 2023, a putative class action lawsuit was filed in the U.S. District Court for the Northern District of California against the company and certain of its officers and current and former members of its board of directors, Bergman v. Caribou Biosciences, Inc., et al., Case Number 23-cv-01742 (Bergman Case).
• On April 22, 2024, the company reached an agreement in principle with plaintiffs to settle the Bergman Case for $3.9 million.
• On October 15, 2024, the court issued an order preliminarily approving the settlement and setting a final settlement approval hearing for February 18, 2025.

Related Party Transactions

• During the three months ended September 30, 2024, we recognized $0.6 million of revenue from our Information Rights Agreement with Pfizer, dated June 29, 2023.
• In June 2024, we received additional shares of convertible preferred stock pursuant to anti-dilution rights associated with the Exclusive License Agreement for Veterinary Therapeutics (as amended, Edge chRDNA License Agreement) with Edge Animal Health (Edge), a private company and related party.
• On May 16, 2023, we entered into an Exclusive License Agreement for Veterinary Therapeutics (CRISPR-Cas9) (Edge Cas9 License Agreement), under which we granted Edge an exclusive worldwide license to certain CRISPR-Cas9 intellectual property rights in the field of veterinary therapeutics.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, stock price fluctuations, and potential dilution from future capital raises.
• Employees were impacted by the workforce reduction announced in July 2024, with 21 positions eliminated.
• Patients may benefit from the company's development of novel cell therapies for cancer and autoimmune diseases if these therapies prove to be safe and effective.
• Suppliers and creditors may be impacted by changes in the company's financial position and its ability to meet its obligations.
• Customers are not directly impacted as the company does not yet have any approved products for sale.

Next Steps

• Continue enrolling patients in the dose expansion phase of the ANTLER trial for CB-010.
• Dose a cohort of approximately 20 2L LBCL patients to evaluate whether partial HLA matching improves patient outcomes in the ANTLER trial.
• Enroll approximately 10 patients who have relapsed following any prior CD19-targeted therapy in a proof-of-concept cohort, which will also incorporate partial HLA matching in the ANTLER trial.
• Report initial data from both new cohorts in the ANTLER trial in the first half of 2025.
• Initiate a pivotal phase 3 clinical trial for CB-010 in 2L LBCL in the second half of 2025, following agreement with the FDA on a pivotal trial design.
• Initiate the GALLOP phase 1 clinical trial for CB-010 in LN and ERL by year-end 2024.
• Continue enrolling patients in the dose escalation portion of the CaMMouflage trial for CB-011.
• Present initial dose escalation data from the CaMMouflage phase 1 clinical trial in the first half of 2025.
• Continue enrolling patients in the dose escalation portion of the AMpLify phase 1 trial for CB-012.
• Provide updates on dose escalation as the AMpLify phase 1 clinical trial advances.
• Final settlement approval hearing for the Bergman Case scheduled for February 18, 2025.

Key Dates

Keywords

Caribou Biosciences, CRISPR, chRDNA, genome-editing, cell therapy, CAR-T, allogeneic, oncology, hematologic malignancies, autoimmune diseases, CB-010, CB-011, CB-012, clinical trials, FDA, RMAT, fast track, orphan drug, biopharmaceutical